Elysium Health, a provider of a new category of scientifically validated dietary supplements, has announced the release of BASIS, an advanced daily supplement designed to target metabolic repair and optimisation.
BASIS is the first of the company's upcoming line of dietary supplements created to support metabolic and cellular health, enhance biological functions such as muscle repair and inflammatory response, and promote healthy ageing with memory and cardiovascular health. With the release of BASIS, Elysium Health sets the stage for the expansion in 2015 of its dietary supplements pipeline.
Created in 2014 to develop a new category of supplements based on sound scientific research, Elysium Health researches, develops, licenses and markets supplements that target biological deficiencies through new pathways that complement diet and exercise. Elysium Health has brought together some of the world's leading scientists and healthcare experts to help guide the discovery and validation of these new supplements.
'Recent technological innovations, combined with advancements in our understanding of basic biological mechanisms, finally give us this opportunity to develop novel products that may provide a meaningful impact on individuals' health,' said Dr Leonard Guarente, co-founder and chief scientist of Elysium Health who has led research efforts at the Massachusetts Institute of Technology (MIT) for 34 years and serves as the director of the Glenn Laboratory for the Science of Aging. 'We are thrilled to introduce BASIS and excited about Elysium's potential to build upon the scientific understanding of how natural compounds can enhance an array of key biological functions, and then translate that knowledge into products that may help people improve and sustain their health.'
Elysium Health has established management and scientific teams that are unprecedented in the dietary supplements industry. Guarente and his two co-founders combine decades of important scientific discovery with experience in areas such as mobile applications and healthcare technologies.
In addition to his work at MIT, Guarente is a pioneer in the study of the genetic and molecular foundations of ageing. His work on the links between diet and physiology includes the identification of a group of enzymes known as sirtuins as key regulators of lifespan.
To support Elysium Health's business structure and mission, Guarente and his two co-founders have structured a scientific advisory board composed of more than 30 of the world's leading industry innovators, scientific researchers and clinicians, including five Nobel laureates.
'Our scientific team is dedicated to the idea of making scientific discovery and advancement accessible, understandable and directly applicable to an individual's health,' Marcotulli said. 'This philosophy forms the core of Elysium Health, a platform that offers consumers an entirely new way to think about managing their health and also provides the world's best researchers a way to bring scientific innovation directly to the public.'
A daily product for metabolic health, BASIS contains two novel compounds. The first, nicotinamide riboside, is a precursor of the critical coenzyme NAD+, which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response and protein folding.
The second component of BASIS is a new polyphenol compound pterostilbene, which, like the NAD+ precursor, promotes metabolic health. Both compounds have been validated in numerous laboratories and been shown to improve metabolic health in scientific studies. BASIS is the first of several Elysium Health products scheduled for release during the next 12–18 months that will target areas such as muscle health, metabolism, brain and cardiovascular function and gut health.